Exploring the progression of angle-closure glaucoma over five years

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Beijing Angle Closure Progression Study aims to investigate the five-year incidence of primary angle closure suspect (PACS) progressing to primary angle closure (PAC) or primary angle closure glaucoma (PACG). This observational study will assess potential risk factors associated with disease progression, providing valuable insights for managing PACS. By understanding the natural history of angle-closure diseases, the study seeks to inform strategies that could prevent severe visual impairment caused by PACG, which is a leading cause of irreversible blindness worldwide.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* "Static" gonioscopy identifying 6 or more clock hours of angle circumference in which the posterior (usually pigmented) trabecular meshwork cannot be seen in both eyes with no peripheral anterior synechiae, and normal intraocular pressure (IOP), optic nerve and visual field.
* Able to provide informed consent

Exclusion Criteria:

* Any evidence of primary angle closure (a narrow angle as defined above, but with PAS and/or IOP \> 21 mmHg) or primary angle closure glaucoma (visual field defect or glaucomatous optic neuropathy).
* Previous intraocular surgery or laser treatment, such as cataract surgery, laser trabeculoplasty, trabeculectomy, laser peripheral iridectomy, and laser iridoplasty
* Sign of prior acute attack, such as glaucomatous fleck, keratic precipitates, or iris atrophy.
* Anterior segment structural abnormalities shown by examination, such as iris or ciliary body tumor.
* Severe health problems precluding follow-up such as end-stage heart disease, kidney disease, or lung disease, or terminal cancer.
* Severe eye diseases, such as cataract, macular disease, and retinal detachment.

Where it's running

• Peking University People's Hospital
  Beijing, Beeijing, China Recruiting

Study contacts

• Study coordinator: Huijuan Wu, M.D. Ph.D.
• Email: dr_wuhuijuan@126.com
• Phone: 8613811293109

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Observing changes in the eye's drainage angle after surgery

  This study looks at how different eye surgeries can help people with glaucoma by checking the changes in their eye drainage angle after the procedures.

  Recruiting Zhongshan Ophthalmic Center, Sun Yat-sen University · Guangzhou, Guangdong · NCT06492538

• Interferon-α Maintenance for Favorable-Risk AML

  This study tests pegylated interferon alfa-2b as maintenance therapy to see if it helps keep favorable-risk AML in remission after initial treatment.

  Recruiting Phase 2 Peking University People's Hospital · Beijing · NCT07925554

• HLH after stem cell transplant: can routine blood tests flag risk in the next week?

  This study tests whether changes in common blood tests and clinical data can predict HLH within seven days after a first allogeneic stem cell transplant.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07905066

• MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC

  This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07894458

• ctDNA testing in newly diagnosed DLBCL or HGBL to predict treatment outcomes

  This study checks if measuring circulating tumor DNA in blood after first-line therapy can predict whether the disease will stay away or come back in people with DLBCL or HGBL.

  Recruiting at 2 sites Peking University People's Hospital · Beijing, Beijing Municipality and 1 other locations · NCT07878351

• LECS with sentinel node navigation for early gastric cancer

  This study tests whether combining LECS with sentinel node navigation can treat early gastric cancer while preserving stomach function in eligible patients.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07857668

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.